Funding Sources (2026)
| Source | Amount | Restrictions/Terms | Renewal |
|---|---|---|---|
| Open Source Medicine Foundation (internal) | $180,000 | None. Editorial independence guaranteed in bylaws. | Annual |
| National Institutes of Health (R03) | $75,000 | NIH open science policy. All data and code public. | Expires Dec 2026 |
| Arnold Foundation (health program) | $120,000 | None. No editorial direction. | Expires June 2027 |
Total annual: $375,000
What We Don't Accept
- Funding from supplement, peptide, or pharmaceutical companies
- "Educational grants" from vendors or industry
- Corporate sponsorships or partnerships
- Affiliate commissions or referral fees
- Advertising or sponsored content
- Consulting fees or speaking honoraria from companies selling covered compounds
Editorial Team
| Name | Role | Affiliations | Other Ventures |
|---|---|---|---|
| Matthew Halma | Lead Editor, Founder | Open Source Medicine Foundation (board); no industry board memberships | Research Tracker platform (non-profit); no consulting relationships |
| Medical Advisory Board | Evidence review & evidence tier assignment | Academic (TBD on recruitment) | To be named and detailed upon appointment |
Purity Testing Programme (§5)
Independence of Testing
- Lab Selection: Contracted independent analytical labs with no relationship to vendors or supplement industry.
- Procurement: Products purchased anonymously by third-party intermediaries. Vendors are blinded to testing.
- Results Reporting: Vendor names included (this is the point). No editorial discretion to suppress results.
- Funding: Testing costs ($8–15K per survey) covered by program grant funds, not vendor sponsorship.
Statements of Potential Conflict
Matthew Halma
Location: Próspera, Honduras (special economic zone) — relevant because regulatory environment is non-standard and may appear to create incentive for less oversight.
Statement: Physical location is personal choice unrelated to this work. OSMF is a U.S. nonprofit with U.S. tax status and full financial transparency. PeptideOS editorial policy is set by U.S. foundation grants, not local jurisdiction.
Research Interests: Investigational IND for PACVS (VitalScan study). This research does not involve therapeutic peptides and creates no conflict with this review project. The study has IRB approval and is registered on ClinicalTrials.gov.
Financial Interests: No equity in supplement, peptide, or pharmaceutical companies. No consulting relationships. No speaking honoraria from industry.
Policy on Changes to Funding
If PeptideOS receives funding from any new source:
- This page is updated immediately, before any new funds are accepted or deployed
- The new source, amount, and any restrictions are disclosed
- Public announcement is made (email list, GitHub issue, website banner)
- If the new source is controversial, community review occurs before integration
If we ever accept funding from a vendor or industry party: It is disclosed at the top of every page, in the editorial masthead, and in the schema metadata. There is no way to miss it.
Annual Renewal
This disclosure is reviewed and updated annually on July 15, coinciding with OSMF fiscal year close. Historical versions are archived with dates.
- 2025 COI Disclosure (archived)
- 2026 COI Disclosure (current — this page) — updated July 12, 2026